About: Will plant-made biopharmaceuticals play a role in the fight against COVID-19?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Will plant-made biopharmaceuticals play a role in the fight against COVID-19? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Will plant-made biopharmaceuticals play a role in the fight against COVID-19?
Creator	Potosí, Luis Potosí, San Rosales-Mendoza, Sergio Salud, La En, Investigación De, Centro Autónoma, Universidad Biomedicina, Y De Biotecnología, Sección De, Ciencias De, Facultad Químicas, Ciencias San, De
topic	covid:96f9e6b75c3611899eb5ac11c03ca4b372bd83a1#this
Source	Medline; PMC
abstract	Given the dramatic impact of the COVID-19 pandemic, it is imperative to divulge all the available technologies with the potential to fight against this virus. Plant biotechnology offers potential solutions to this pandemic through the development of low-cost vaccines and antibodies useful for therapy, prophylaxis, and diagnosis. The technology to produce plant-made biopharmaceuticals is already established; two examples of these are: a therapeutic enzyme that has entered the market and the influenza vaccines that are currently under clinical trials with encouraging results. Thus far, some companies have started developing anti-COVID-19 antibodies and vaccines. In particular, plant-made antibodies might be timely produced and approved for human use in the short term, while the development of vaccines will take longer time (clinical evaluations could be concluded by the end of 2021); nonetheless, the candidates obtained will be valuable tools for future outbreaks. The key aspects that will define the exploitation of this technology in the fight against COVID-19 are discussed.
has issue date	2020-04-13(xsd:dateTime)
bibo:doi	10.1080/14712598.2020.1752177
bibo:pmid	32250170
has license	no-cc
sha1sum (hex)	96f9e6b75c3611899eb5ac11c03ca4b372bd83a1
schema:url	https://doi.org/10.1080/14712598.2020.1752177
resource representing a document's title	Will plant-made biopharmaceuticals play a role in the fight against COVID-19?
has PubMed Central identifier	PMC7157952
has PubMed identifier	32250170
schema:publication	Expert Opin Biol Ther
resource representing a document's body	covid:96f9e6b75c3611899eb5ac11c03ca4b372bd83a1#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/96f9e6b75c3611899eb5ac11c03ca4b372bd83a1
is schema:about of	named entity 'COVID-19' named entity 'tools' named entity 'biotechnology' named entity 'produce' named entity 'timely' named entity 'antibodies' named entity 'time' named entity 'pandemic' named entity 'prophylaxis' named entity 'biopharmaceuticals' named entity 'biopharmaceuticals' named entity 'protein' named entity 'cell cultures' named entity 'virus' named entity 'Infectious Disease Research' named entity 'antibodies' named entity 'biopharmaceuticals' named entity 'virus' named entity 'vaccine' named entity 'COVID' named entity 'COVID-19' named entity 'transgenic plants' named entity 'transmissibility' named entity 'protein' named entity 'antibody' named entity 'biopharmaceuticals' named entity 'antibodies' named entity 'SARS-CoV-1' named entity 'antibody' named entity '10 million' named entity 'emerging diseases' named entity 'parenteral' named entity 'recombinant proteins' named entity 'low-income countries' named entity 'taliglucerase alfa' named entity 'secretory IgA' named entity 'antibodies' named entity 'COVID' named entity 'COVID-19 vaccine' named entity 'Medicago' named entity 'mucosal' named entity 'antigen' named entity 'low-income countries' named entity 'influenza' named entity 'COVID' named entity 'pandemics' named entity 'SARS-CoV-2 virus' named entity 'Coronavirus' named entity 'SARS-CoV-2 virus' named entity 'cGMP' named entity 'SARS-CoV-1' named entity 'SARS-CoV-2 virus' named entity 'genetic engineering' named entity 'pathogen' named entity 'SARS-CoV-2 virus' named entity 'vaccine' named entity 'biotechnology' named entity 'H1N1 pandemic' named entity 'Injectable' named entity 'cross-react' named entity 'injectable' named entity 'current Good Manufacturing Practices' named entity 'Molecular farming' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'monoclonal antibody' named entity 'prophylaxis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software